At longtradr.com we often look for companies that stand the test of time, businesses that not only survive but thrive for decades. Novo Nordisk fits that profile. Founded in 1923 in Denmark, it has spent over a century becoming a global leader in diabetes care, obesity treatment and rare chronic diseases.
Because it has lasted so long and continues to innovate, Novo Nordisk can confidently be considered a Lindy effect stock — meaning the longer it has existed, the longer it is likely to continue existing.
And right now, something interesting is happening: the share price is down, the 3-month RSI is deeply oversold, and the price sits below the 200-day moving average. That combination has often been a strong signal for long-term investors to start paying attention.
Why Is Novo Nordisk Trading Lower?
As of late September 2025, Novo Nordisk’s ADR (ticker: NVO) is trading around 55 to 65 dollars, which is a noticeable drop from its highs earlier this year.
So why the decline? There are a few factors in play:
- Investors have rotated out of pharmaceutical stocks in general following a wave of profit-taking after obesity-related stocks surged in 2023 and 2024.
- Increased competition from other players in the obesity drug market, particularly from Eli Lilly, has raised concerns about pricing power.
- Some recent clinical trial updates were solid but not groundbreaking, which caused short-term disappointment for momentum traders.
But while the short-term narrative may sound cautious, the technical indicators tell another story.
The 3-month RSI has now dropped to a level below 50, which historically has been rare for NVO. Each time the RSI reached this depth in the past five years, the stock eventually rebounded strongly.
Moreover, the share price is now below the 200-day moving average, a level that has often marked strong long-term entry points. Together, these signals could offer a solid risk-reward profile for patient investors.
Lindy Logic and a Strong Pipeline
Being a Lindy stock means more than just having history. It also means the business model is built to last.
Novo Nordisk has entrenched itself in the global healthcare system with core strengths in:
- Insulin and GLP-1 based therapies for diabetes
- Next-generation obesity treatments, including semaglutide-based drugs
- Rare endocrine disorders and cardiovascular disease management
Looking ahead, several potential catalysts are worth noting:
- Expansion into oral GLP-1 formulations, which could open up new patient groups
- Further regulatory approvals in new markets, especially in Asia and Latin America
- Ongoing R&D in metabolic and liver diseases, areas with growing global demand
- Potential for new partnerships or acquisitions, as Novo Nordisk looks to stay ahead in an increasingly competitive space
Even during uncertain market conditions, the company’s consistency in execution and its focus on essential long-term health challenges make it one of the strongest candidates in the healthcare sector.
longtradr.com Ratings
Category: Lindy Company Score
★★★★☆
Over 100 years in business, a trusted name in healthcare, and a strong pipeline make Novo Nordisk a near-textbook example of a Lindy stock. The only reason it is not a perfect 5 is due to increasing competition and pricing pressures in the obesity segment.
Category: Entry Timing (RSI & MA)
★★★★☆
With a deeply oversold 3-month RSI and price under the 200-day average, the current setup looks very attractive for long-term investors. Momentum could take time to return, but history suggests this is a sweet spot for accumulation.
For long-term thinkers, Novo Nordisk is a company worth watching closely. Whether you are building a healthcare-heavy portfolio or simply looking for Lindy exposure with real-world utility, this could be one of the more interesting opportunities right now.
